Alkermes Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 2,050

Employees

  • Stock Symbol
  • ALKS

Stock Symbol

  • Investments
  • 15

  • Share Price
  • $47.03
  • (As of Friday Closing)

Alkermes General Information

Description

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Contact Information

Website
www.alkermes.com
Formerly Known As
Antler Science Two
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Connaught House
  • 1 Burlington Road
  • Dublin D04 C5Y6
  • Ireland
+353 (01)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Manufacturing
Corporate Office
  • Connaught House
  • 1 Burlington Road
  • Dublin D04 C5Y6
  • Ireland
+353 (01)

Alkermes Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alkermes Stock Performance

As of 13-Nov-2026, Alkermes’s stock price is $47.03. Its current market cap is $7.9B with 168M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$47.03 $46.98 $27.00 - $55.67 $7.9B 168M 1.89M

Alkermes Financials Summary

As of 30-Sep-2026, Alkermes has a trailing 12-month revenue of $1.75B.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 7,713,755 3,580,472 4,110,579 4,125,113
Revenue 1,753,599 1,475,899 1,557,632 1,663,405
EBITDA 146,168 285,588 452,411 488,624
Net Income (351) 241,664 367,070 355,757
Total Assets 4,435,523 2,486,993 2,055,567 2,136,223
Total Debt 1,571,081 69,999 75,538 372,185
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alkermes Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alkermes‘s full profile, request access.

Request a free trial

Alkermes Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop,
Drug Discovery
Dublin, Ireland
2,050 As of 2026

Monmouth Junction, NJ
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alkermes Competitors (37)

One of Alkermes’s 37 competitors is Tris Pharma, a Private Debt Financed company based in Monmouth Junction, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tris Pharma Private Debt Financed Monmouth Junction, NJ
Novartis Corporation Basel, Switzerland
Nevian Lifescience Corporate Backed or Acquired Dhaka, Bangladesh
Cipla Corporation Mumbai, India
Hoechst Pakistan Corporate Backed or Acquired Karachi, Pakistan
You’re viewing 5 of 37 competitors. Get the full list »

Alkermes Patents

  • 2,167

    Total Documents Applications and Grants

  • Total Patents Families

  • 976

    Granted

  • 100

    Pending

  • Expiring in next 12 mo

Alkermes Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4801885-A1 Synthesis of intermediates for the preparation of macrocyclic compounds Pending 30-Oct-2023
WO-2025096445-A1 Synthesis of intermediates for the preparation of macrocyclic compounds Inactive 30-Oct-2023
AU-2024361979-A1 Compound for use in treating narcolepsy Pending 20-Oct-2023
EP-4794690-A1 Compound for use in treating narcolepsy Pending 20-Oct-2023
US-20250186405-A1 Compound for use in treating narcolepsy Pending 20-Oct-2023 A61K31/4353
To view Alkermes’s complete patent history, request access »

Alkermes Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alkermes Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alkermes‘s full profile, request access.

Request a free trial

Alkermes Investments & Acquisitions (15)

Alkermes’s most recent deal was a Merger/Acquisition with Avadel Pharmaceuticals for . The deal was made on 12-Feb-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Avadel Pharmaceuticals 12-Feb-2026 Merger/Acquisition Pharmaceuticals
Rodin Therapeutics 25-Nov-2019 Merger/Acquisition Drug Discovery
Civitas Therapeutics 25-Aug-2014 Later Stage VC Drug Delivery
Synchronicity Pharma 26-Nov-2013 Later Stage VC Drug Discovery
Civitas Therapeutics 11-Sep-2013 Early Stage VC Drug Delivery
You’re viewing 5 of 15 investments and acquisitions. Get the full list »

Alkermes ESG

Risk Overview

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Alkermes’s complete esg history, request access »

Alkermes Exits (8)

Alkermes’s most recent exit was on 25-Aug-2014 from Civitas Therapeutics. The exit was categorized as with 12 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Civitas Therapeutics 25-Aug-2014 Completed
  • 12 buyers
Civitas Therapeutics 11-Sep-2013 Completed
  • 6 buyers
Acceleron Pharma 23-Dec-2011 Completed
  • 15 buyers
Civitas Therapeutics 12-Jul-2011 Completed
  • 4 buyers
Acceleron Pharma 15-Dec-2009 Later Stage VC Completed
You’re viewing 5 of 8 exits. Get the full list »

Alkermes Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Avadel Pharmaceuticals Dublin, Ireland 2015
Medisorb Perm, Russia 1993

Alkermes FAQs

  • When was Alkermes founded?

    Alkermes was founded in 1987.

  • Where is Alkermes headquartered?

    Alkermes is headquartered in Dublin, Ireland.

  • What is the size of Alkermes?

    Alkermes has 2,050 total employees.

  • What industry is Alkermes in?

    Alkermes’s primary industry is Drug Discovery.

  • Is Alkermes a private or public company?

    Alkermes is a Public company.

  • What is Alkermes’s stock symbol?

    The ticker symbol for Alkermes is ALKS.

  • What is the current stock price of Alkermes?

    As of 13-Nov-2026 the stock price of Alkermes is $47.03.

  • What is the current market cap of Alkermes?

    The current market capitalization of Alkermes is $7.9B.

  • What is Alkermes’s current revenue?

    The trailing twelve month revenue for Alkermes is $1.75B.

  • Who are Alkermes’s competitors?

    Tris Pharma, Novartis, Nevian Lifescience, Cipla, and Hoechst Pakistan are some of the 37 competitors of Alkermes.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process